⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

January 30, 2026Molecular Therapy — Nucleic AcidsOpen Access

RNA-based discovery and correction of splicing defects caused by POLR3A missense mutations

Lulzim Shkreta Aurélie Delannoy Johanne Toutant James A. McSwiggen Benoı̂t Chabot

View Full Paper

Ask AI

Bookmark

Share

Key Points

Splicing defects were identified due to POLR3A missense mutations, impacting gene function and expression.
Around 20% of mutations led to significant splicing alterations, underscoring a critical link between genetics and cellular processes.
Analysis utilized RNA sequencing to pinpoint defects in splicing associated with POLR3A mutations across multiple models.
Findings highlight the need for further research into molecular mechanisms and potential therapeutic interventions.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Observational analysis reveals splicing defects caused by POLR3A mutations in diverse models, suggesting potential corrections.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shkreta et al. (2026) studied this question.

synapsesocial.com/papers/69a75e9ec6e9836116a29654 https://doi.org/10.1016/j.omtn.2026.102850

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Reframing nonsense variants in genodermatoses through personalized molecular rescueMolecular Therapy — Nucleic Acids · 2026
2Gibson assembly in human cellsMolecular Therapy — Nucleic Acids · 2026
3A new contender enters the race for cystic fibrosis gene therapyMolecular Therapy — Nucleic Acids · 2026
4Paloma Giangrande appointed for a second term as the editor-in-chief of Molecular Therapy Nucleic AcidsMolecular Therapy — Nucleic Acids · 2026
5Beyond lysosomal storage: Correcting Fabry cardiomyocyte dysfunction with modified GLA mRNAMolecular Therapy — Nucleic Acids · 2026
6PIWIL2: A new link between RNA biology, inflammation, and ischemic brain injuryMolecular Therapy — Nucleic Acids · 2026
7Therapeutic silencing of serine/threonine kinase 25 for obesity-associated MASLDMolecular Therapy — Nucleic Acids · 2026
8Expanding synthetic lethality through computationally designed aptamersMolecular Therapy — Nucleic Acids · 2026
9Beyond repressor disruption: Designing activator motifs to boost fetal hemoglobinMolecular Therapy — Nucleic Acids · 2026
10AAV encoding miRNAs as a new therapeutic for choroidal neovascularizationMolecular Therapy — Nucleic Acids · 2026

More from Molecular Therapy — Nucleic Acids

More from Université de Sherbrooke

More from Quebec Rehabilitation Research Network

More from 490 BioTech (United States)